Health & Biotech
Headquartered in Auckland, New Zealand, Aroa Biosurgery is a soft-tissue regeneration company committed to unlocking regenerative healing for everybody through its patented AROA ECM™ complex wound and tissue reconstruction products.
The company was founded in 2008 by Veterinarian Surgeon Dr Brian Ward, who discovered that a tissue scaffold called the extra cellular matrix (ECM) found in the forestomach of sheep has a similar structure to human tissue and contains over 150 proteins known to be important in the healing process.
Listed on the ASX since 2020, Aroa Biosurgery has established USA operations, regulatory approval in over 50 countries and employs over 270 people in New Zealand and North America.
Over 6 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. www.aroabio.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
Skin in the game: Why investing in founder-led companies can pay off
Health & Biotech
Scott Power: Which health stock bled this week after an earnings downgrade?
News
Closing Bell: ASX jumps higher again, 4DMedical wins US FDA approval
Health & Biotech
Aroa’s study shows Myriad’s impact in lower limb surgery
Health & Biotech
Aroa looks to save lower limbs with Myriad
Health & Biotech
Scott Power: Which ASX healthcare stock has soared 30pc this week?
Stockhead TV
Long Shortz with Aroa Biosurgery: Plenty of drivers into profitability for H2 FY25
Health & Biotech
Aroa product revenue up 27pc as Myriad sales drive growth
Health & Biotech
Health Check: Biotech double-banger breaks the IPO drought
Health & Biotech
Scott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?
Health & Biotech
Scott Power: Which ASX health stocks reaffirm FY25 guidance?
Stockhead TV
Long Shortz with Aroa Biosurgery: Puzzle pieces coming together for success in H2 FY25
Health & Biotech
Aroa rises with positive operating cash flow targeted in H2 FY25
Health & Biotech
Health Check: Latest biotech quarterly results are as patchy as the curate’s egg
Health & Biotech
Scott Power: ASX health stocks rise as focus shifts to reporting season
Health & Biotech
Aroa looks to capitalise on growing US wound care market
Health & Biotech